Effect of Fas Triggering on Colony Growth From BM of Normal Subjects and CML Patients
| Cell Type . | Total BM Cells . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Control . | Anti-Fas . | CD34+ Cells . | . | |||||||
| . | Erythroid . | Myeloid . | Erythroid . | Myeloid . | Control . | Anti-Fas . | . | . | . | ||
| . | . | . | . | . | Erythroid . | Myeloid . | Erythroid . | Myeloid . | . | . | . |
| Normal | |||||||||||
| Untreated | 100 | 100 | 81 ± 2 | 99 ± 1 | 100 | 100 | 89 ± 8 | 97 ± 3 | |||
| IFN-α 15 U/mL | 73 ± 2 | 89 ± 2 | 43 ± 7 | 45 ± 2 | ND | ND | ND | ND | |||
| IFN-α 100 U/mL | 62 ± 9 | 79 ± 2 | 25 ± 2 | 36 ± 4 | 66 ± 9 | 83 ± 3 | 39 ± 3 | 34 ± 2 | |||
| IFN-α 1,000 U/mL | 31 ± 1 | 60 ± 5 | 12 ± 1 | 26 ± 1 | 31 ± 4 | 55 ± 1 | 22 ± 1 | 31 ± 2 | |||
| CML | |||||||||||
| Untreated | 100 | 100 | 53 ± 17 | 62 ± 19 | 100 | 100 | 44 ± 5 | 37 ± 2 | |||
| IFN-α 15 U/mL | 95 ± 5 | 81 ± 6 | 27 ± 7 | 21 ± 10 | ND | ND | ND | ND | |||
| IFN-α 100 U/mL | 73 ± 20 | 62 ± 5 | 21 ± 22 | 27 ± 14 | 86 ± 5 | 80 ± 5 | 19 ± 8 | 16 ± 9 | |||
| IFN-α 1,000 U/mL | 53 ± 15 | 52 ± 15 | 9 ± 9 | 13 ± 8 | 80 ± 5 | 53 ± 1 | 9 ± 9 | 9 ± 8 | |||
| Cell Type . | Total BM Cells . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Control . | Anti-Fas . | CD34+ Cells . | . | |||||||
| . | Erythroid . | Myeloid . | Erythroid . | Myeloid . | Control . | Anti-Fas . | . | . | . | ||
| . | . | . | . | . | Erythroid . | Myeloid . | Erythroid . | Myeloid . | . | . | . |
| Normal | |||||||||||
| Untreated | 100 | 100 | 81 ± 2 | 99 ± 1 | 100 | 100 | 89 ± 8 | 97 ± 3 | |||
| IFN-α 15 U/mL | 73 ± 2 | 89 ± 2 | 43 ± 7 | 45 ± 2 | ND | ND | ND | ND | |||
| IFN-α 100 U/mL | 62 ± 9 | 79 ± 2 | 25 ± 2 | 36 ± 4 | 66 ± 9 | 83 ± 3 | 39 ± 3 | 34 ± 2 | |||
| IFN-α 1,000 U/mL | 31 ± 1 | 60 ± 5 | 12 ± 1 | 26 ± 1 | 31 ± 4 | 55 ± 1 | 22 ± 1 | 31 ± 2 | |||
| CML | |||||||||||
| Untreated | 100 | 100 | 53 ± 17 | 62 ± 19 | 100 | 100 | 44 ± 5 | 37 ± 2 | |||
| IFN-α 15 U/mL | 95 ± 5 | 81 ± 6 | 27 ± 7 | 21 ± 10 | ND | ND | ND | ND | |||
| IFN-α 100 U/mL | 73 ± 20 | 62 ± 5 | 21 ± 22 | 27 ± 14 | 86 ± 5 | 80 ± 5 | 19 ± 8 | 16 ± 9 | |||
| IFN-α 1,000 U/mL | 53 ± 15 | 52 ± 15 | 9 ± 9 | 13 ± 8 | 80 ± 5 | 53 ± 1 | 9 ± 9 | 9 ± 8 | |||
Values (mean ± SD) represent colony formation as a percentage of untreated normal and CML progenitors. Five experiments were performed with total BM cells and 2 with purified CD34+ cells. The mean number of colonies in control cultures was 162 ± 17 erythroid and 63 ± 3 myeloid/105 total BM cells plated, and 147 ± 21 erythroid and 78 ± 8 myeloid/103 purified CD34+ cells plated. The mean number of colonies in CML cultures was 257 ± 35 erythroid and 97 ± 17 myeloid for total BM, and 397 ± 45 erythroid and 124 ± 14 myeloid for CD34+ cells. Anti-Fas MoAb CH11 (anti-Fas) was used at a concentration of 1 μg/mL. Statistical analysis (paired t-test): Control cultures, control v anti-Fas, P < .05; control v IFN-α (15, 100, and 1,000 U/mL), P < .05 in total BM and CD34+ cells; control v 15 U/mL IFN-α + anti-Fas, P < .05; control v 100 and 1,000 U/mL IFN-α + anti-Fas, P < .01 in total BM, and control v 100 and 1,000 U/mL IFN-α + anti-Fas, P < .05 in CD34+ cells. CML cultures, control v anti-Fas, P < .01; control v IFN-α (15, 100, and 1,000 U/mL), P < .05 in total BM and CD34+ cells; control v IFN-α (15, 100, and 1,000 U/mL) + anti-Fas, P < .01 in total BM; control v IFN-α (100 and 1,000 U/mL) + anti-Fas, P < .05 in CD34+ cells.